Publication | Closed Access

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

Rheumatoid DisorderRheumatologyMedicineImmunologyBiological TherapyInflammatory Rheumatic DiseasePharmacotherapyRheumatoid ArthritisRheumatoid Arthritis PatientsPsoriatic Arthritis5-Year Drug SurvivalEpidemiologyHellenic Registry